**Exhibit
      31.1**


CERTIFICATION








I,
      Geoffrey W. Henson, certify that:





1. I
      have reviewed this quarterly report on Form 10-QSB of FermaVir Pharmaceuticals,
      Inc.;





2. Based
      on my knowledge, this quarterly report does not contain any untrue statement
      of
      a material fact or omit to state a material fact necessary to make the
      statements made, in light of the circumstances under which such statements
      were
      made, not misleading with respect to the period covered by this quarterly
      report;





3. Based
      on my knowledge, the financial statements, and other financial information
      included in this quarterly report, fairly present in all material respect the
      financial condition, results of operations and cash flows of the registrant
      as
      of, and for, the periods presented in this quarterly report.





4. The
      registrant’s other certifying officers and I am responsible for establishing and
      maintaining disclosure controls and procedures (as defined in Exchange Act
      Rules
      13a-14 and 15d-14) for the registrant and have:





a)
            designed
                such disclosure controls and procedures to ensure that material
                information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities,
                particularly during the period in which this quarterly report is
                being
                prepared;





b)
            evaluated
                the effectiveness of the registrant’s disclosure controls and procedures
                as of a date within 90 days prior to the filing date of this quarterly
                report (the “Evaluation Date”); and





c)
            presented
                in this quarterly report our conclusions about the effectiveness
                of the
                disclosure controls and procedures based on our evaluation as of
                the
                Evaluation Date;





5. The
      registrant’s other certifying officers and I have disclosed, based on our most
      recent evaluation, to the registrant’s auditors and the audit committee of
      registrant’s Board of Directors (or persons performing the equivalent
      functions):




a)
              all
                    significant deficiencies in the design or operation of internal
                    controls
                    which could adversely affect the registrant’s ability to record, process,
                    summarize and report financial data and have identified for the
                    registrant’s auditors any material weaknesses in internal controls;
                    and
 b)
                any
                      fraud, whether or not material, that involves management or
                      other
                      employees who have a significant role in the registrant’s internal
                      controls; and


6. The
      registrant’s other certifying officers and I have indicated in this quarterly
      report whether or not there were significant changes in internal controls or
      in
      other factors that could significantly affect internal controls subsequent
      to
      the date of our most recent evaluation, including any corrective actions with
      regard to significant deficiencies and material weaknesses.





September
      15, 2005




/s/
                Geoffrey W. HensonGeoffrey
                  W. Henson, President
                Chief
                  Executive and Financial Officer